产品名称
Anti-MDM2 (Ab-5) Mouse mAb (4B2C1.11), liquid, clone 4B2C1.11, Calbiochem®
form
liquid
biological source
mouse
antibody form
purified antibody
antibody product type
primary antibodies
clone
4B2C1.11, monoclonal
does not contain
preservative
species reactivity
human
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
avoid repeated freeze/thaw cycles
dilution
(Immunoblotting (2 µg/mL, chemiluminescence)
Immunofluorescence (2.5 µg/mL)
Immunoprecipitation (1 µg/reaction,
Paraffin Sections (2.5 µg/mL, heat pre-treatment required))
isotype
IgG1
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... MDM2(4193)
Analysis Note
Positive Control
A549 or MCF7 cells or breast carcinoma tissue
A549 or MCF7 cells or breast carcinoma tissue
Application

Immunoblotting (2 g/ml, chemiluminescence)
Immunofluorescence (2.5 g/ml)
Immunoprecipitation (1 g/reaction, see application references)
Paraffin Sections (2.5 g/ml, heat pre-treatment required)
Disclaimer
Toxicity: Standard Handling (A)
General description
Purified mouse monoclonal antibody. Recognizes the ~90 kDa (apparent MW) MDM2 protein.
Recognizes the ~90 kDa (apparent MW) MDM2 protein in A549 and MCF-7 cells and breast carcinoma tissue.
This Anti-MDM2 (Ab-5) Mouse mAb (4B2C1.11) is validated for use in Immunoblotting, Immunofluorescence, Immunoprecipitation, Paraffin Sections for the detection of MDM2 (Ab-5).
Immunogen
Human
recombinant, human MDM2
Other Notes
Antibody should be titrated for optimal results in individual systems.
Marchetti, A., et al. 1995. J. Pathol.175, 31.
Barak, Y., et al. 1993. EMBO. J.12, 461.
Ladanyi, M., et al. 1993. Cancer Res.53, 16.
Leach, F.S., et al. 1993. Cancer Res.53, 2231.
Oliner, J.D., et al. 1993. Nature362, 857.
Momand, J., et al. 1992. Cell69, 1237.
Oliner, J.D., et al. 1992. Nature358, 80.
Fakharzadeh, S.S., et al. 1991. EMBO J.10, 1565.
Barak, Y., et al. 1993. EMBO. J.12, 461.
Ladanyi, M., et al. 1993. Cancer Res.53, 16.
Leach, F.S., et al. 1993. Cancer Res.53, 2231.
Oliner, J.D., et al. 1993. Nature362, 857.
Momand, J., et al. 1992. Cell69, 1237.
Oliner, J.D., et al. 1992. Nature358, 80.
Fakharzadeh, S.S., et al. 1991. EMBO J.10, 1565.
Packaging
Please refer to vial label for lot-specific concentration.
Physical form
In 50 mM sodium phosphate buffer, 50% glycerol, pH 7.5.
Preparation Note
Following initial thaw, aliquot and freeze (-20°C).
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品?
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 3
Paula M Hauck et al.
Molecular cancer research : MCR, 15(11), 1598-1607 (2017-08-09)
Metastasis of cancer cells to distant organ systems is a complex process that is initiated with the programming of cells in the primary tumor. The formation of distant metastatic foci is correlated with poor prognosis and limited effective treatment options.
Xiongbin Lu et al.
Cancer cell, 12(4), 342-354 (2007-10-16)
The tumor suppressor p53 is a transcription factor that responds to cellular stresses by initiating cell cycle arrest or apoptosis. One transcriptional target of p53 is Mdm2, an E3 ubiquitin ligase that interacts with p53 to promote its proteasomal degradation
A Carpentieri et al.
Cell death & disease, 6, e1974-e1974 (2015-11-13)
Current hypothesis suggest that tumors can originate from adult cells after a process of 'reprogramming' driven by genetic and epigenetic alterations. These cancer cells, called cancer stem cells (CSCs), are responsible for the tumor growth and metastases. To date, the
Daniel Garcia et al.
Genes & development, 25(16), 1746-1757 (2011-08-20)
MdmX, also known as Mdm4, is a critical negative regulator of p53, and its overexpression serves to block p53 tumor suppressor function in many cancers. Consequently, inhibiting MdmX has emerged as an attractive approach to restoring p53 function in those
Weijia Cai et al.
Nature communications, 10(1), 5800-5800 (2019-12-22)
p53 acetylation is indispensable for its transcriptional activity and tumor suppressive function. However, the identity of reader protein(s) for p53 acetylation remains elusive. PBRM1, the second most highly mutated tumor suppressor gene in kidney cancer, encodes PBRM1. Here, we identify
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持